As of January 22, 2025, Bavarian Nordic (BAVA.CO) has a market cap of $2.20 billion USD. According to our data, Bavarian Nordic is ranked No.3990 in global market value.
Year | Market Cap | %Change |
---|---|---|
Jan 22, 2025 | $2.20 B |
6.21%
|
Dec 30, 2024 | $2.07 B |
6.71%
|
Dec 29, 2023 | $1.94 B |
-16.85%
|
Dec 30, 2022 | $2.33 B |
-20.61%
|
Dec 30, 2021 | $2.94 B |
43.74%
|
Dec 30, 2020 | $2.04 B |
37.88%
|
Dec 30, 2019 | $1.48 B |
34.52%
|
Dec 28, 2018 | $1.10 B |
-43.18%
|
Dec 29, 2017 | $1.94 B |
-9.92%
|
Dec 30, 2016 | $2.15 B |
-30.35%
|
Dec 30, 2015 | $3.09 B |
81.01%
|
Dec 30, 2014 | $1.71 B |
121.91%
|
Dec 30, 2013 | $0.77 B |
78.71%
|
Dec 28, 2012 | $0.43 B |
29.69%
|
Dec 30, 2011 | $0.33 B |
-79.79%
|
Dec 30, 2010 | $1.64 B |
102.74%
|
Dec 30, 2009 | $0.81 B |
8.71%
|
Dec 30, 2008 | $0.74 B |
-55.13%
|
Dec 28, 2007 | $1.66 B |
-46.63%
|
Dec 29, 2006 | $3.11 B |
22.27%
|
Dec 30, 2005 | $2.54 B |
-4.05%
|
Dec 31, 2004 | $2.65 B |
115.17%
|
Dec 31, 2003 | $1.23 B |
134.11%
|
Dec 31, 2002 | $0.53 B |
24.06%
|
Dec 31, 2001 | $0.42 B |
-45.57%
|
Dec 29, 2000 | $0.78 B |
100%
|
Name | Market Cap | Market cap difference | Regions |
---|---|---|---|
GlaxoSmithKline
GSK
|
$68.38 B |
0.002 M
|
UK
|
Merck
MRK
|
$242.59 B |
0.007 M
|
USA
|
Pfizer
PFE
|
$148.34 B |
-0.006 M
|
USA
|
Sanofi
SNY
|
$128.55 B |
0.003 M
|
France
|
AstraZeneca
AZN
|
$211.43 B |
0.005 M
|
UK
|
Johnson & Johnson
JNJ
|
$347.78 B |
-0.005 M
|
USA
|
Moderna
MRNA
|
$14.88 B |
0.000 M
|
USA
|
Novavax
NVAX
|
$1.42 B |
-0.000 M
|
USA
|
BioNTech
BNTX
|
$27.52 B |
-0.001 M
|
Germany
|
Inovio Pharmaceuticals
INO
|
$78.32 M |
-0.000 M
|
USA
|
Dynavax Technologies
DVAX
|
$1.64 B |
-0.022 B
|
USA
|
Emergent BioSolutions
EBS
|
$0.58 B |
-0.000 M
|
USA
|
VBI Vaccines
VBIV
|
$1.87 M |
1.514 M
|
USA
|
Sea (Garena)
SE
|
$68.00 B |
5.390 B
|
Singapore
|
Curevac
CVAC
|
$0.88 B |
0.000 M
|
Germany
|
Market Cap | = | BAVA.CO Stock Price | * | BAVA.CO Shares Outstanding |
= | $28.08 | * | 78.21 M | |
= | $2.20 B |